Atezolizumab plus bevacizumab therapy is thought to exert its antitumour effect through the combined effects of an ICI plus an anti-VEGF inhibitor, by suppressing immunosuppressive Tregs, restoring the immune activity of CD8+ cells [25], normalizing the tumour vasculature, promoting CD8+ cell infiltration into the tumour [26], and inducing cell death and subsequent cancer antigen release through direct antitumour and necrotic effects [27,28]. This evidence concerns the gene CD8A and cancer.